Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.

ABSTRACT:

Background

Immunotherapy is an ideal treatment modality to specifically target the diffusely infiltrative tumor cells of malignant gliomas while sparing the normal brain parenchyma. However, progress in the development of these therapies for glioblastoma has been slow due to the lack of immunogenic antigen targets that are expressed uniformly and selectively by gliomas.

Methods

We utilized human glioblastoma cell cultures to induce expression of New York-esophageal squamous cell carcinoma (NY-ESO-1) following in vitro treatment with the demethylating agent decitabine. We then investigated the phenotype of lymphocytes specific for NY-ESO-1 using flow cytometry analysis and cytotoxicity against cells treated with decitabine using the xCelligence real-time cytotoxicity assay. F

SUBMITTER: Everson RG 

PROVIDER: S-EPMC4767237 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature